BPC-157 and TB-500: The Tissue-Repair Synergy Stack

BPC-157 and TB-500 are the two most cited research peptides in soft-tissue repair literature. They are frequently studied together because their mechanisms are complementary rather than overlapping — combining them in a research protocol hits two different parts of the healing cascade at the same time.

BPC-157: cytoprotection and angiogenesis

BPC-157 (Body Protection Compound, a pentadecapeptide) is a synthetic fragment of a protective protein found in human gastric juice. It has been studied extensively by Sikiric and colleagues at the University of Zagreb across hundreds of animal models.

In published research, BPC-157 has been shown to:

• Accelerate tendon-to-bone healing and ligament repair
• Increase angiogenesis (new capillary formation) via VEGF and eNOS upregulation
• Protect the gastric, intestinal, and esophageal mucosa
• Modulate the gut–brain axis through vagal signalling
• Restore impaired wound healing in compromised models (NSAID injury, corticosteroid suppression)

The distinct feature of BPC-157 is its stability — it remains active in gastric juice, which is why oral research forms are studied alongside subcutaneous and intramuscular routes.

TB-500: actin remodelling and cell migration

TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), the most abundant actin-sequestering protein in mammalian cells. Where BPC-157 protects tissue, TB-500 mobilises it.

Published work shows TB-500 / Tβ4:

• Sequesters G-actin and regulates actin polymerization, enabling cell movement
• Promotes endothelial and stem-cell migration into damaged tissue
• Suppresses inflammatory cytokine production (TNF-α, IL-6, IL-8)
• Accelerates corneal, dermal, and cardiac wound healing in animal models
• Drives reactivation of dormant progenitor populations

The peptide's reach is unusual — it has a long systemic half-life and crosses tissue barriers efficiently, which is why a single weekly dose is common in research literature.

Why combine them

The two peptides target different stages of the repair cascade:

Stage	BPC-157	TB-500
Cytoprotection	strong	modest
Angiogenesis	strong	moderate
Cell migration	moderate	strong
Actin remodelling	minimal	strong
Anti-inflammatory	moderate	strong
Gut/vagal effects	strong	minimal

Using them together in research lets investigators probe whether protection + migration produces faster or more complete repair than either alone. Published comparisons in animal models support this combined effect.

Common research dose ranges

Reported research ranges in the literature:

• BPC-157: 250–500 mcg per day subcutaneously, typically split or once-daily, in cycles of 4–8 weeks
• TB-500: 2–5 mg per week, often front-loaded for 4 weeks (loading phase) then dropped to 2–2.5 mg every 1–2 weeks (maintenance)

A typical research stacking schedule observed in literature:

Phase	BPC-157	TB-500	Duration
Loading	500 mcg/day	5 mg/week	4 weeks
Maintenance	250 mcg/day	2.5 mg/week	4–8 weeks
Wash-out	—	—	4 weeks

Dose figures above are reference figures observed in published peptide research literature. They are not medical advice or recommendations for human use.

Reconstitution example

A 10 mg vial of BPC-157 reconstituted with 2 mL BAC water gives 5 mg/mL. A 250 mcg dose is 0.05 mL — 5 units on a U-100 insulin syringe.

A 10 mg vial of TB-500 reconstituted with 2 mL BAC water gives 5 mg/mL. A 2.5 mg weekly dose is 0.5 mL — 50 units on a U-100 insulin syringe.

Both peptides are refrigerated at 2–8 °C after reconstitution. Research stability references describe 4–6 weeks for BPC-157 and 6–8 weeks for TB-500 under cold storage.

Stacking with GHK-Cu

Many research protocols extend the stack with GHK-Cu for gene-expression remodelling of the repair tissue. The three peptides do not compete mechanistically — they layer cleanly.

Use the ZORVYN Dose Calculator to verify reconstitution math for any vial size and BAC water volume.